Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R932333 · 1 trial · 2 indications
Percentage of patients who achieved at least a 50% decrease from baseline in the total combined Erythema and Scaling score of all treated lesions at Week 4. A decrease is an improvement in measurement of erythema and scaling of the lesions.
| Arm | Type | Description |
|---|---|---|
| Drug: R932333 | ACTIVE_COMPARATOR | R333 6% (60 mg/g), bid |
| Placebo | PLACEBO_COMPARATOR | Placebo, bid |
| Name | Type | Description |
|---|---|---|
| R932333 | DRUG | R393233 6% (60 mg/g), bid |
| Placebo | DRUG | Placebo, bid |
Inclusion Criteria: * Diagnosis of SLE or DLE (DLE confirmed histologically prior to randomization). * At least 2 active discoid lesions secondary to SLE or DLE prior to study entry, each with a minimum Erythema Rating Score of ≥ 2. At least 1 of the active discoid lesions must have been present (b...
R932333 is an investigational small molecule being studied for the treatment of discoid lupus erythematosus (DLE) and systemic lupus erythematosus (SLE) skin lesions. It is applied topically and has completed a Phase 2 clinical trial in patients with these conditions.
R932333 is a small molecule developed by Rigel Pharmaceuticals. Its specific molecular target has not been disclosed in the available information. The drug is being investigated for its effects on skin lesions in lupus erythematosus, but the exact mechanism of action is not publicly detailed.
R932333 is being developed by Rigel Pharmaceuticals, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RIGL. The company is conducting clinical research on this investigational drug for lupus-related skin conditions.
R932333 has completed a Phase 2 clinical trial. The trial, identified as NCT01597050, was a randomized, double-blind, placebo-controlled study that has been completed. R932333 remains an investigational drug and is not approved by regulatory authorities.
R932333 has been studied in one clinical trial, NCT01597050, titled 'Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions.' This Phase 2 trial enrolled 54 participants in the United States and Canada and has been completed.
R932333 is also known as R333. The clinical trial NCT01597050 refers to the drug as 'Topical R333,' indicating that R932333 and R333 are alternative names for the same investigational compound being developed by Rigel Pharmaceuticals.